345 related articles for article (PubMed ID: 18347008)
1. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial.
Schmidt H; Brown J; Mouritzen U; Selby P; Fode K; Svane IM; Cook GP; Mollerup DH; Geertsen PF
Clin Cancer Res; 2010 Nov; 16(21):5312-9. PubMed ID: 20959407
[TBL] [Abstract][Full Text] [Related]
3. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
7. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
[TBL] [Abstract][Full Text] [Related]
8. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
14. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
15. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
18. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC; Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
20. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
